89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4099-8
Abstract: BackgroundUp-to-date information on human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) is important, as expression can vary during the course of the disease, necessitating anti-HER2 therapy adjustments. Repeat biopsies, however, are… read more here.
Keywords: status; decision; her2 status; 89zr trastuzumab ... See more keywords
Clinical value of Zr-89-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs16-p5-03-06
Abstract: Background: Information on human epidermal growth factor receptor 2 (HER2) is essential for management of metastatic breast cancer (mBC). In patients suspected of HER2-positive mBC, standard work up may fail to clarify whole body HER2… read more here.
Keywords: trastuzumab pet; 89zr trastuzumab; her2; cancer ... See more keywords